Your session is about to expire
← Back to Search
MK-1088 for Solid Tumors
Study Summary
This trial will study the safety and effectiveness of the drug MK-1088 as a possible treatment for advanced solid tumors.
- Advanced Solid Tumors
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have had another type of cancer in the past, but it's okay if it has been treated completely and there has been no sign of it for at least 2 years.You have a stomach or liver condition that could affect how your body absorbs or processes oral medications.You have a history of a lung disease called interstitial lung disease.You have received a transplant of stem cells or a solid organ from another person in the past.You have been diagnosed with an advanced or metastatic solid tumor, and have either received, had issues with, or were not eligible for a treatment that is known to provide clinical benefit.You have recently had a major surgery and are still recovering from it.You have cancer that has spread to your brain or lining of the brain.You have an autoimmune disease that has needed treatment throughout your whole body in the last 2 years.You have a history of lung inflammation that needed treatment with steroids, or you currently have lung inflammation.
- Group 1: MK-1088
- Group 2: MK-1088 + Pembrolizumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many individuals are included in this experiment?
"In order to conduct this research, we need 80 individuals who fit the bill of our inclusion criteria. Those chosen can come from various locations, such as Laura and Isaac Perlmutter Cancer Center ( Site 0102) in New york or University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 0103) down in Florida."
In how many different medical institutions is this research project being conducted presently?
"So far, there are 5 locations that are running this trial. For example, in New york there is the Laura and Isaac Perlmutter Cancer Center (Site 0102). Additionally, University of Miami Hospital and Clinics, Sylvester Cancer Center (Site 0103) in Miami, Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0201) in Toronto are also participating. There are 5 other locations not mentioned."
What are the key goals that researchers are hoping to achieve with this clinical trial?
"The primary goal of this trial, which will last for approximately 24 months, is to evaluate the number of patients experiencing an adverse event. Additionally, the study team will also be measuring the objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1). ORR is defined as the percentage of participants who have a Complete Response or Partial Response according to RECIST 1.1 guidelines. Lastly, they will also report on the maximum plasma concentration (Cmax) of MK-1088 and ORR per Prostate cancer Working Group (PCWG)-modified RECIST 1"
Are people currently being accepted into this experiment?
"This study, which was originally posted on July 7th 2022, is currently seeking patients. The clinical trial was last edited on October 20th 2022."
Popular Categories
Share this study with friends
Copy Link
Messenger